2012年　業績集

  1. Yamada S, Sato F, Xia H, Takino H, Kominato S, Ri M, Ishida T, Iida S, Inagaki H, Yamada K. Forkhead box P1 overexpression and its clinicopathological significance in peripheral T-cell lymphoma, not otherwise specified. Human Pathol. 2012; 43: 1322-1327.
  2. Hosen N, Ichihara H, Mugitani A, Aoyama Y, Fukuda Y, Kishida S, Matsuoka Y, Nakajima H, Kawakami M, Yamagami T, Fujii S, Tamaki H, Nakano T, Nishida S, Tsuboi A, Iida S, Hino M, Oka Y, Oji Y, Sugiyama H. CD48 as a novel molecular target for antibody therapy in multiple myeloma. Br J Haematol 2012; 156: 213-224.
  3. Yoshizawa S, Ohyashiki J, Suzuki K, Iida S, Ohyashiki K. Down-regulated plasma miR-92a levels have clinical impact in multiple myeloma and related disorders. Blood Cancer J 2012; 2(1): e53.
  4. Mori F, Ishida T, Ito A, Sato F, Masaki A, Takino H, Ri M, Kusumoto S, Komatsu H, Ueda R, Inagaki H, Iida S. Potent antitumor effects of bevacizumab in a microenvironment-dependent human lymphoma mouse model. Blood Cancer J 2012; 2(4): e67.
  5. * Ri M, Tashiro E, Oikawa D, Shinjo S, Tokuda M, Yokouchi Y, Narita T, Masaki A, Ito A, Ding J, Kusumoto S, Ishida T, Komatsu H, Shiotsu Y, Ueda R, Iwawaki T, Imoto M, Iida S. Identification of toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicing. Blood Cancer J 2012; 2(7): e79.
  6. Suzuki S, Masaki A, Ishida T, Ito A, Mori F, Sato F, Ri M, Kusumoto S, Komatsu H, Fukumori Y, Nishikawa H, Tanaka Y, Inagaki H, Iida S, Ueda R. Tax is a potential molecular target for immunotherapy of adult T-cell leukemia/lymphoma. Cancer Sci 2012; 103: 1764-1773.
  7. Suzuki T, Ota Y, Ri M, Bando M, Tsumoto H, Tatum PR, Nakagawa H, Iida S, Ueda R, Shirahige K, Miyata N. Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries. J Med Chem 2012; 55: 9562-9575.
  8. Shimura Y, Kuroda J, Ri M, Nagoshi H, Yamamoto-Sugitani M, Kobayashi T, Kiyota M, Nakayama R, Mizutani S, Chinen Y, Sakamoto N, Matsumoto Y, Horiike S, Shiotsu Y, Iida S, Taniwaki M. RSK2Ser227 at N-terminal kinase domain as therapeutic target for multiple myeloma. Mol Cancer Ther 2012; 11: 2600-2609.
  9. Akechi T, Okuyama T, Uchida M, Nakaguchi T, Sugano K, Kubota Y, Ito Y, Kizawa Y, Komatsu H. Clinical indicators of depression among ambulatory cancer patients undergoing chemotherapy. Jpn J Clin Oncol. 2012;42(12):1175-80.
  10. Wakita A, Ohtake S, Takada S, Yagasaki F, Komatsu H, Miyazaki Y, Kubo K, Kimura Y, Takeshita A, Adachi Y, Kiyoi H, Yamaguchi T, Yoshida M, Ohnishi K, Miyawaki S, Naoe T, Ueda R, Ohno R. Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 Study. Int J Hematol. 2012; 96(1):84-93.
  11. Akechi T, Okuyama T, Uchida M, Nakaguchi T, Ito Y, Yamashita H, Toyama T, Komatsu H, Kizawa Y, Wada M. Perceived needs, psychological distress and quality of life of elderly cancer patients. Jpn J Clin Oncol. 2012; 42(8):704-10
  12. Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, Saburi Y, Miyamoto T, Takemoto S, Suzushima H, Tsukasaki K, Nosaka K, Fujiwara H, Ishitsuka K, Inagaki H, Ogura M, Akinaga S, Tomonaga M, Tobinai K, Ueda R. Defucosylated Anti-CCR4 Monoclonal Antibody (KW-0761) for Relapsed Adult T-Cell Leukemia-Lymphoma: A Multicenter Phase II Study. J Clin Oncol, 2012; 30:837-42. (corresponding author)
  13. Ishida T, Hishizawa M, Kato K, Tanosaki R, Fukuda T, Taniguchi S, Eto T, Takatsuka Y, Miyazaki Y, Moriuchi Y, Hidaka M, Akashi K, Uike N, Sakamaki H, Morishima Y, Kato K, Suzuki R, Nishiyama T, Utsunomiya A. Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study. Blood. 2012 Aug 23; 120(8):1734-41. (corresponding author)
  14. *Nishikawa H, *Maeda Y, *Ishida T, Gnjatic S, Sato E, Mori F, Sugiyama D, Ito A, Fukumori Y, Utsunomiya A, Inagaki H, Old LJ, Ueda R, Sakaguchi S. Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma. Blood 2012; 119:3097-104. (*equally contributed)
  15. Tsuboi K, Yamamoto H. Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal). Genetics in Medicine 2012; Sep; 14(9): 779-86.
  16. Tsuboi K, Suzuki S, Nagai M. Descriptive Epidemiology of Fabry Disease Among Beneficiaries of the Specified Disease Treatment Research Program in Japan. Journal of Epidemiology 2012; 22(4): 370-4.
  17. Liu Q, Kirubakaran S, Hur W, Niepel M, Westover K, Thoreen CC, Wang J, Ni J, Patricelli MP, Vogel K, Riddle S, Waller DL, Traynor R, Sanda T, Zhao Z, Kang SA, Zhao J, Look AT, Sorger PK, Sabatini DM, Gray NS. Kinome-wide Selectivity Profiling of ATP-competitive Mammalian Target of Rapamycin (mTOR) Inhibitors and Characterization of Their Binding Kinetics. J Biol Chem. 2012 Mar 23; 287(13):9742-52.
  18. Kentsis A, Reed C, Rice K, Sanda T, Rodig SJ, Tholouli E, Christie A, Valk P, Delwel R, Ngo V, Kutok JL, Dahlberg SE, Moreau LA, Byers RJ, Christensen JG, Woude GV, Licht Kung AL, Staudt LM, Look AT. Aberrant expression of hepatocyte growth factor induces autocrine activation of MET, providing a novel therapeutic target in acute myeloid leukemia. Nature Med, 2012 Jul; 18(7):1118-22
  19. Berry T, Luther W, Bhatnagar N, Jamin Y, Poon E, Sanda T, Pei D, Sharma B, Vetharoy WR, Hallsworth A, Ahmad Z, Barker K, Moreau L, Webber H, Wang W, Liu Q, Perez-Atayde A, Rodig S, Cheung N, Raynaud F, Hallberg B, Robinson SP, Gray NS, Pearson ADW, Eccles SA, Chesler L, George RE. The ALKF1174L mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell, 2012, Jul 10; 22(1):117-30.
  20. Sanda T, Lawton LN, Barrasa MI, Fan ZP, Kohlhammer H, Gutierrez A, Ma W, Tatarek J, Ahn Y, Kelliher MA, Jamieson CHM, Staudt LM, Young RA, and Look AT. Core transcriptional regulatory circuit controlled by the TAL1 complex in human T-cell acute lymphoblastic leukemia. Cancer Cell, 2012 Aug 14; 22(2):209-21.
  21. Ando K, Kernan JL, Liu PH, Sanda T, Logette E, Tschopp J, Look AT, Wang J, Bouchier-Hayes L, and Sidi S. PIDD Death-Domain Phosphorylation by ATM Controls Prodeath Versus Prosurvival PIDDosome Signaling, Mol Cell, 2012 Sep 14;47(5):681-93
  22. Choi YJ, Li X, Hydbring P, Sanda T, Stefano J, Christie AL, Signoretti S, Look AT, Kung AL, von Boehmer H, Sicinski P. The requirement for cyclin d function in tumor maintenance. Cancer Cell. 2012 Oct 16; 22(4):438-51.
  23. Weisberg E, Liu Q, Nelson E, Kung AL, Christie AL, Bronson R, Sattler M, Sanda T, Zhao Z, Hur W, Mitsiades C, Smith R, Daley JF, Stone R, Galinsky I, Griffin JD, Gray N. Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors, and JAK inhibitors. Leukemia. 2012 Oct; 26(10):2233-44